Semax 10mg is a synthetic peptide derived from the 4-10 fragment of the adrenocorticotropic hormone (ACTH). Developed in Russia during the 1980s, this neuropeptide was initially designed to prevent and treat circulatory disorders and acute cerebral hypoxia, often resulting from traumatic brain injuries.

Although Semax 10 mg has not yet received FDA approval, research has demonstrated its potential benefits. Studies suggest that Semax may enhance memory, improve mental clarity, and elevate dopamine levels in the brain. It is also thought to have neuroprotective effects.

In clinical trials, Semax 5mg has shown promise. For example, in a study with 100 participants, Semax was found to accelerate the recovery of brain functions when added to standard treatments. Another trial indicated that Semax 5mg could potentially reduce brain damage and lower the risk of future strokes in patients with compromised cerebral blood flow.